Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults
| Autor: | Robyn McCall-Sani, Shelly A. McNeil, Simon Dobson, Dan Levitt, Bruce Smith, Gary Van Nest, Joanne M. Langley, Daniel Gennevois, Joseph Eiden, Scott A. Halperin |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male medicine.medical_specialty Hepatitis B vaccine Adolescent Oligonucleotides medicine.disease_cause Placebo Gastroenterology Adjuvants Immunologic Orthohepadnavirus Internal medicine medicine Humans Hepatitis B Vaccines Hepatitis B Antibodies Adverse effect Hepatitis B virus Hepatitis B Surface Antigens General Veterinary General Immunology and Microbiology biology business.industry Immunogenicity Public Health Environmental and Occupational Health Thionucleotides biology.organism_classification Infectious Diseases Hepadnaviridae Immunology Toxicity Molecular Medicine Female business |
| Zdroj: | Vaccine. 24:20-26 |
| ISSN: | 0264-410X |
| Popis: | Background Many individuals do not respond to a three-dose series of hepatitis B vaccine (HBV) and most do not achieve a protective antibody response until after dose 2 or 3. Methods Healthy, seronegative 18–28 year old adults were randomly assigned in equal numbers to receive two doses of the experimental vaccine (HBV-ISS without alum) (0, 8 weeks) and placebo (24 weeks) or Engerix-B® (0, 8, 24 weeks). Adverse events were collected during the first week and at 4 weeks after each injection. Antibodies were measured 4 weeks after dose 1; before, 1 and 4 weeks after dose 2, and before, 1 and 4 weeks after dose 3 and at 1 year. Results Ninety-nine participants were enrolled (65% female; mean age 22.6 years). 79% of HBV-ISS and 12% of Engerix-B® recipients had a protective antibody response 4 weeks post dose 1 (geometric mean concentration [GMC] 23.0 and 1.87 mIU/mL, respectively). By 1 week post dose 2, 100% of HBV-ISS and 18% Engerix-B® recipients had protective levels (GMC 1603 versus 2.40 mIU/mL). Rates of adverse events were low and similar in both groups; headache and fatigue were the most common systemic adverse events in up to 1/3 of both groups. Mild injection-site tenderness was more common after HBV-ISS than Engerix-B® after both doses (74–77% compared to 34–58%; p ≤ 0.029). Conclusions Protective levels are achieved more quickly and after fewer doses of HBV-ISS than Engerix-B®. HBV-ISS is well tolerated but associated with more mild injection-site tenderness than Engerix-B®. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect